TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21693027

Group type: EXPERIMENTAL
Intervention: Culturally adapted Problem Solving Therapy (C-MAP), 8 sessions lasting approximately 50 minutes each over 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 20015817

Group type: EXPERIMENTAL
Intervention: Removal of the transurethral catheter on the first postoperative day (Group 1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Removal of the catheter after discontinuation of PCEA (Group 2)
Number of subjects: 78
Study: 22054688

Group type: EXPERIMENTAL
Intervention: Blood Conservation System (BCS)
Number of subjects: 216

Group type: COMPARATOR
Intervention: 3-way stopcock
Number of subjects: 216
Study: 16230866

Group type: EXPERIMENTAL
Intervention: BNP-guided up-titration of beta blocker
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care (clinical group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups (BNP and standard care)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BNP group
Number of subjects: 41
Study: 12746760

Group type: EXPERIMENTAL
Intervention: 30 mg Pioglitazone once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 60
Study: 10228112

Group type: EXPERIMENTAL
Intervention: HLA class II polymorphism (specifically DR4 and DR7 alleles)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: HLA class II polymorphism (specifically DR7 allele)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (39 subjects without atopy)
Number of subjects: 98
Study: 7503047

Group type: EXPERIMENTAL
Intervention: High intake of vitamin C and beta-carotene (mean intakes: 138 mg/day vitamin C, 5.3 mg/day beta-carotene)
Number of subjects: 1556
Study: 2141231

Group type: EXPERIMENTAL
Intervention: Body mechanics instruction (one classroom session and two on-site sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no body mechanics instruction)
Number of subjects: 30
Study: 108187

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Membrane oxygenator
Number of subjects: 40
Study: 11598528

Group type: EXPERIMENTAL
Intervention: Levator anus massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild levator stretch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31196835

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study: 30328176

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% triclosan + 2.0% PVM/MA copolymer + 1,450 ppm fluoride (test)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Toothpaste containing 1,450 ppm fluoride (control)
Number of subjects: 102
Study: 26745832

Group type: EXPERIMENTAL
Intervention: Active balance-point training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham balance-point training
Number of subjects: 63
Study: 24074457

Group type: EXPERIMENTAL
Intervention: Intranasal inhalation of 24 IU of oxytocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study: 22618520

Group type: EXPERIMENTAL
Intervention: Nitroglycerine with Lipiodol emulsion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (without nitroglycerine)
Number of subjects: 101
Study: 20197785

Group type: EXPERIMENTAL
Intervention: A. bisporus alpha‐glucans (5 g glucans/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control fruit juice (200 ml/day)
Number of subjects: 56
Study: 17628352

Group type: EXPERIMENTAL
Intervention: Reserpine (0.5 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 16376736

Group type: EXPERIMENTAL
Intervention: Patients' preferences for desired experiences during the last week of life
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Conversations about treatment preferences
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Surrogates' understanding of patients' preferences
Number of subjects: 92
Study: 12408201

Group type: EXPERIMENTAL
Intervention: Culturally tailored self-help nutrition and PA intervention (TX1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally tailored self-help nutrition and PA intervention plus four telephone counseling calls based on MI (TX2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard (existing commercial) nutrition and PA intervention materials (Group 1)
Number of subjects: 0
Study: 10205584

Group type: EXPERIMENTAL
Intervention: Bedtime uncooked cornstarch (0.3 g kg‐1 body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional snack (wholemeal bread, 0.6 g of carbohydrates kg‐1 body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate-free placebo
Number of subjects: 12
Study: 7842183

Group type: EXPERIMENTAL
Intervention: Heliox (80:20 helium:oxygen) for 15 min
Number of subjects: 27

Group type: COMPARATOR
Intervention: Room air for 15 min (control)
Number of subjects: 27
Study: 2222979

Group type: EXPERIMENTAL
Intervention: Instromedix Baro-Graf QD home blood pressure monitor
Number of subjects: 40
Study: 417644

Group type: EXPERIMENTAL
Intervention: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose and fructose
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: L-amino acid solutions (0.24 g N/kg body weight/day) + glucose, fructose, and fat emulsions (30-40% of total calories, 30 kcal/kg body weight/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 31876947

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy for chronic pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group chronic pain self-management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (taper only)
Number of subjects: 0
Study: 30828718

Group type: EXPERIMENTAL
Intervention: Expression of RNase T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCA-adding enzyme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altered catalytic efficiency and temperature sensitivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional enzyme variants
Number of subjects: 0
Study: 27324506

Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan) 20-600 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan) 200 mg with food
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26688235

Group type: EXPERIMENTAL
Intervention: Methotrexate (3.5 g/m²) with temozolomide (150 mg/m²)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Methotrexate (3.5 g/m²), procarbazine (100 mg/m²), vincristine (1.4 mg/m²), and cytarabine (3 mg/m²)
Number of subjects: 98
Study: 23421759

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 12 months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (lactose monohydrate and stearic acid, same weight as zinc capsules)
Number of subjects: 200
Study: 21424975

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normobaric oxygen therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mitochondrial complex IV (mtCIV) activity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxidative stress (lipid peroxidation)
Number of subjects: 60
Study: 19429632

Group type: EXPERIMENTAL
Intervention: Pre-hospital fibrinolysis (rt-PA)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Primary angioplasty
Number of subjects: 840
Study: 16601659

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: HIV-uninfected women
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Geographic site (Blantyre)
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Geographic site (Lilongwe)
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Geographic site (Lusaka)
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: HIV infection status
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Age 20 to 24 years
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Marital status (divorced, widowed, or separated)
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Genital ulcer treatment in the last year
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: History of stillbirth
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: History of preterm delivery
Number of subjects: 2636
Study: 14578918

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between losartan and atenolol
Number of subjects: 120
Study: 10391568

Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (sent correspondence, print material, and telephone contacts tailored to each recipient)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Minimal intervention group (mailed a letter and reminder to invite to urology clinic)
Number of subjects: 548
Study: 8536887

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 1910096

Group type: EXPERIMENTAL
Intervention: NaHCO3 (bicarbonate loading)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CaCO3)
Number of subjects: 8
Study: 6749426

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Participants who dropped out
Number of subjects: 1012
Study: 30475006

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention for alcohol use
Number of subjects: 35
Study: 28294985

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus rhamnosus CGMCC1.3724)
Number of subjects: 105
Study: 25085275

Group type: EXPERIMENTAL
Intervention: GS 500 mg/CS 400 mg three times daily capsules (GI)
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: GS 500 mg/CS 400 mg once daily sachet (GII)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: GH 500 mg/CS 400 mg three times daily (GIII)
Number of subjects: 1120
Study: 23588112

Group type: EXPERIMENTAL
Intervention: Growth-arrested neonatal dermal fibroblasts and keratinocytes delivered via pump spray in a fibrin sealant-based matrix, plus a foam dressing and four-layer compression bandaging for 12 weeks or until healed.
Number of subjects: 228

Group type: COMPARATOR
Intervention: Vehicle control (no active treatment).
Number of subjects: 228
Study: 21915478

Group type: EXPERIMENTAL
Intervention: L-thyroxine replacement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 19506099

Group type: EXPERIMENTAL
Intervention: BQ-123
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 22
Study: 17029610

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (100 microg weekly for 52 weeks)
Number of subjects: 76
Study: 12772754

Group type: EXPERIMENTAL
Intervention: Menicon Z RGP lenses worn continuously for 30 days (29 nights)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acuvue hydrogel lenses worn for 7 days (6 nights)
Number of subjects: 0
Study: 11194701

Group type: EXPERIMENTAL
Intervention: Stage-based smoking control program
Number of subjects: 65

Group type: COMPARATOR
Intervention: General health education control condition
Number of subjects: 65
Study: 9754162

Group type: EXPERIMENTAL
Intervention: 1000‐centistoke silicone oil as the retinal tamponade
Number of subjects: 2439
Study: 7546107

Group type: EXPERIMENTAL
Intervention: Nonpolymer underpads
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Polymer underpads
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cloth underpads
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Diaper products
Number of subjects: 166

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 166
Study: 3042637

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 30333014

Group type: EXPERIMENTAL
Intervention: YogaFit
Number of subjects: 40

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 40
Study: 28238203

Group type: EXPERIMENTAL
Intervention: JNJ‐53718678 (single doses of 25-1000 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: JNJ‐53718678 (multiple doses of 250 mg every 24 h, 500 mg q24h, 250 mg every 12 h for 8 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: JNJ‐53718678
Number of subjects: 9
Study: 26275644

Group type: EXPERIMENTAL
Intervention: Routine prenatal care and music listening (experimental group)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Routine prenatal care only (control group)
Number of subjects: 296
Study: 24139587

Group type: EXPERIMENTAL
Intervention: Self-inserted foreign body (SIFB) group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SIFB group
Number of subjects: 45
Study: 20215977

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET) - conjugated equine estrogens 0.625 mg daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Estrogen + progesterone therapy (EPT) - ET plus medroxyprogesterone acetate 2.5 mg daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 18198066

Group type: EXPERIMENTAL
Intervention: Access to personal antenatal health records (PI group)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Access to general pregnancy health information (GI group)
Number of subjects: 193
Study: 16834970

Group type: EXPERIMENTAL
Intervention: Ruanjian Xiaoying Decoction (RJXYD) combined with levothyroxine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Levothyroxine and prednisone
Number of subjects: 80
Study: 12076344

Group type: EXPERIMENTAL
Intervention: Active IFC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham IFC
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 30
Study: 10445673

Group type: EXPERIMENTAL
Intervention: Levosimendan (18 or 36 microg/kg loading dose and 0.2 or 0.3 microg/kg/min infusion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levosimendan (high-dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levosimendan (both doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 18
Study: 7788690

Group type: EXPERIMENTAL
Intervention: Wiktor stent
Number of subjects: 65

Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 65
Study: 2229946

Group type: EXPERIMENTAL
Intervention: skills training plus incentive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: skills training only
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo plus incentive
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo without incentive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: skills training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: incentive
Number of subjects: 60
Study: 316786

Group type: EXPERIMENTAL
Intervention: Portacaval shunt surgical treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: No surgical treatment (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Presence of large esophageal varices
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Two episodes of gastrointestinal bleeding within one year
Number of subjects: 80
Study: 6354422

Group type: EXPERIMENTAL
Intervention: Superfractionation (SF) radiation therapy (4000 rad in 45 fractions in 3 weeks whole brain and 1000 rad in five fractions in one week local boost)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional Fractionation (CF) radiation therapy (3400 rad in 17 fractions whole brain in 3.5 weeks and 1600 rad in eight fractions in 1.5 weeks local boost)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Superfractionation (SF) radiation therapy
Number of subjects: 69
Study: 31282028

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo (plus standard of care therapy)
Number of subjects: 9340
Study: 29432959

Group type: EXPERIMENTAL
Intervention: 12 SQ‐HDM (sublingual immunotherapy tablet)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 25248311

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 90

Group type: COMPARATOR
Intervention: No Tourniquet
Number of subjects: 90
Study: 24128654

Group type: EXPERIMENTAL
Intervention: Salmon consumption (two 150 g portions of farmed salmon per week from 20 weeks of pregnancy to delivery)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Salmon group infants
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123
Study: 22397774

Group type: EXPERIMENTAL
Intervention: Sedoanalgesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Periprostatic blockage (PPB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intrarectal gel instillation
Number of subjects: 100
Study: 18629526

Group type: EXPERIMENTAL
Intervention: 75 mg venlafaxine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17604558

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (EG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 15848575

Group type: EXPERIMENTAL
Intervention: Early Neoral (day 0)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Delayed Neoral (day 6)
Number of subjects: 197
Study: 11882931

Group type: EXPERIMENTAL
Intervention: r‐HuEPO+intravenous iron (EPO+IV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: r‐HuEPO+oral iron (EPO+OR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (both groups)
Number of subjects: 21
Study: 10531077

Group type: EXPERIMENTAL
Intervention: DMARD and prednisolone (mean dose 6 mg, mean cumulated dose 2160 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: DMARD alone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: DMARD and prednisolone
Number of subjects: 76
Study: 7789045

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inhibition of angiotensin-converting enzyme (lisinopril)
Number of subjects: 8
Study: 2112177

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 to 1.0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 483170

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 27
Study: 30327952

Group type: EXPERIMENTAL
Intervention: Brush-off patch containing 3.0% hydrogen peroxide applied for 10 min twice daily (case 10 group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Brush-off patch containing 3.0% hydrogen peroxide applied for 30 min once daily (case 30 group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study: 29211893

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (8-week period)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lean participants
Number of subjects: 78

Group type: COMPARATOR
Intervention: Abdominally obese participants
Number of subjects: 78
Study: 26918556

Group type: COMPARATOR
Intervention: Miglitol (50 mg) just before breakfast (intake schedule B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Miglitol dissolved in water (50 mg) taken just before, during, and just after breakfast (intake schedule C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No miglitol (intake schedule A)
Number of subjects: 0
Study: 24128798

Group type: EXPERIMENTAL
Intervention: Six-stage method (SSM)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Descriptive teaching method
Number of subjects: 134
Study: 21930328

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3117

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (ACCEPT trial)
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (ACCEPT trial)
Number of subjects: 3117
Study: 20133410

Group type: EXPERIMENTAL
Intervention: Post-recruitment confirmation of informed consent by SMS
Number of subjects: 553
Study: 17993823

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 53

Group type: COMPARATOR
Intervention: Balafilcon A lenses
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Daily-wear basis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Continuous-wear basis
Number of subjects: 53
Study: 16390409

Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 100 days
Number of subjects: 381

Group type: COMPARATOR
Intervention: Ganciclovir prophylaxis for 100 days
Number of subjects: 381
Study: 12447737

Group type: EXPERIMENTAL
Intervention: Pneumococcal carriage among older siblings in DCCs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pneumococcal strains from older siblings' DCCs
Number of subjects: 36

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 36
Study: 10669899

Group type: EXPERIMENTAL
Intervention: Tettuccio mineral water
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 14
Study: 7549411

Group type: EXPERIMENTAL
Intervention: Caffeine (3.5 mg/kg in 200 ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg made up to 200 ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (200 ml)
Number of subjects: 8
Study: 119270

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CF 25‐397
Number of subjects: 15

Group type: COMPARATOR
Intervention: Apomorphine
Number of subjects: 15
Study: 31020351

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 156